Clik here to view.
Endpoints 11 winner Metsera: Clive Meanwell wagers on obesity after Medicines...
↑ CEO Clive Meanwell Total raised $290 million Headquarters New York, NY Shortly after Clive Meanwell sold The Medicines Company to Novartis for nearly $10 billion in 2020, he started a life sciences...
View ArticleClik here to view.
Endpoints 11 winner Ascidian Therapeutics: A search-and-replace technology...
↑ CEO Michael Ehlers Total raised $90 million Headquarters Boston, MA Ascidian Therapeutics has a secret list of nearly 400 diseases that its gene-altering technology might help cure. But you’ll only...
View ArticleClik here to view.
Endpoints 11 winner Cardurion Pharmaceuticals: A shot at one of heart...
↑ CEO Peter Lawrence Total raised More than $500 million Headquarters Burlington, MA ‘Undruggable’ targets aren’t just in oncology. Cardurion Pharmaceuticals is hoping to become the first to...
View ArticleClik here to view.
Endpoints 11 winner Iambic Therapeutics: Entering the ‘show-me’ era for AI
↑ CEO Tom Miller Total raised $220 million Headquarters San Diego, CA As two biotech rookies leaving long academic careers to co-found Iambic in 2019, CEO Tom Miller and CTO Fred Manby were...
View ArticleClik here to view.
Endpoints 11 winner Lifordi Immunotherapeutics: Using antibodies to deliver...
↑ CEO Arthur Tzianabos Total raised $70 million Headquarters Burlington, MA As a young scientist, Jay Rothstein asked fellow immunologists what they thought the biggest unsolved problem in the field...
View ArticleClik here to view.
Endpoints 11 winner MediLink Therapeutics: China startup helps power the ADC...
↑ CEO Tony Xue Total raised $120 million Headquarters Suzhou, China In the ADC renaissance of the last few years, Japan’s venerable pharma company Daiichi Sankyo has won many of the headlines. But if...
View ArticleThe Endpoints 11 2024 winners: Big bets on AI, new frontiers in editing, a...
What makes a great biotech startup? Every year, the Endpoints 11 awards try to answer that question. We’ve spent the last several months examining dozens of finalists, talking to investors and biotech...
View ArticleClik here to view.
The worst is over for digital health funding, PitchBook report says
While the worst of the funding slump for digital health startups since the lofty highs of the pandemic seems to be drawing to an end, the uptick may be gradual. Venture investors poured $1.5 billion...
View ArticleClik here to view.
Steve Davis leaves Acadia, replaced by Bristol Myers alum; Former J&J exec to...
Steve Davis → Steve Davis is out as CEO of Acadia Pharmaceuticals, passing the baton to Catherine Owen Adams. Davis was named CEO in 2015, and a year into his tenure, he led Acadia to the FDA approval...
View ArticleCassava and its former execs settle SEC charges for ‘misleading’ Alzheimer’s...
Cassava Sciences and two of its former executives have reached a resolution with the SEC over charges of “misleading” investors about the strength of data from a mid-stage Alzheimer’s disease study....
View ArticleClik here to view.
Travere halts Phase 3 inherited disease trial due to manufacturing scale-up...
Travere Therapeutics said there is a “voluntary pause” in recruitment to its Phase 3 study in a rare, inherited disorder due to issues in scaling up its production process. The company said enrollment...
View ArticleClik here to view.
FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and...
The biggest drug driving Sanofi’s and Regeneron’s businesses is about to get a bit bigger. On Friday, the FDA approved Dupixent as an add-on to typical inhaled medicines for patients with inadequately...
View ArticleWeightWatchers replaces CEO who spearheaded its push into prescription weight...
WeightWatchers said Friday that its CEO Sima Sistani, who shifted the weight loss giant’s strategy to prescribing obesity drugs, is stepping down from her role, effective immediately. The company...
View ArticleClik here to view.
Novo Nordisk to decrease some insulin pen manufacturing, transition supply
Novo Nordisk has told government and global nonprofits that it plans to significantly downsize its manufacturing of some of its insulin pens, according to one of the groups, and will transition a...
View ArticleUS government renews threats over J&J's proposed 340B rebate model
The federal government renewed its threats to Johnson & Johnson on Friday over the company’s proposal to change how some hospitals receive drug price discounts under the 340B program. The company...
View ArticleClik here to view.
For some multiple myeloma patients, Carvykti cut risk of death by 45%
Johnson & Johnson and Legend Biotech’s CAR-T cell therapy Carvykti reduced the risk of death by 45% compared to standard of care at almost three years for a portion of multiple myeloma patients,...
View ArticleMeet this year’s Endpoints 11; J&J winds down cardiovascular and metabolic...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleUpdated: Pfizer to further decrease stake in consumer health company Haleon
Pfizer has continued shrinking its ownership in the British consumer health company Haleon. The New York drugmaker sold 640 million shares, raising about $3.26 billion in gross proceeds, according to...
View ArticleJ&J pulls the plug on 340B rebate model changes opposed by government
Johnson & Johnson has called off plans to implement a new rebate model for 340B drug price discounts following threats from the federal government. While continuing to defend the legality of the...
View ArticleCalifornia's Gavin Newsom vetoes bipartisan PBM reform bill
California Gov. Gavin Newsom vetoed bipartisan legislation on Saturday that would have reformed pharmacy benefit managers in the state, prompting the bill’s author to call the decision “a massive...
View Article